KR20170007818A - 박테리아 감염의 치료를 위한 융합된，스피로환식 헤테로방향족 화합물 - Google Patents

박테리아 감염의 치료를 위한 융합된，스피로환식 헤테로방향족 화합물 Download PDF

Info

Publication number
KR20170007818A
KR20170007818A KR1020167035906A KR20167035906A KR20170007818A KR 20170007818 A KR20170007818 A KR 20170007818A KR 1020167035906 A KR1020167035906 A KR 1020167035906A KR 20167035906 A KR20167035906 A KR 20167035906A KR 20170007818 A KR20170007818 A KR 20170007818A
Authority
KR
South Korea
Prior art keywords
spp
mycoplasma
fluoro
oxazolidin
oxazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167035906A
Other languages
English (en)
Korean (ko)
Inventor
마이클 허밴드
Original Assignee
엔타시스 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔타시스 테라퓨틱스 리미티드 filed Critical 엔타시스 테라퓨틱스 리미티드
Publication of KR20170007818A publication Critical patent/KR20170007818A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020167035906A 2014-05-29 2015-05-27 박테리아 감염의 치료를 위한 융합된，스피로환식 헤테로방향족 화합물 Ceased KR20170007818A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
US62/004,246 2014-05-29
PCT/IB2015/001585 WO2015181637A1 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Publications (1)

Publication Number Publication Date
KR20170007818A true KR20170007818A (ko) 2017-01-20

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167035906A Ceased KR20170007818A (ko) 2014-05-29 2015-05-27 박테리아 감염의 치료를 위한 융합된，스피로환식 헤테로방향족 화합물

Country Status (14)

Country Link
US (1) US10238661B2 (https=)
EP (1) EP3148546A1 (https=)
JP (1) JP6502387B6 (https=)
KR (1) KR20170007818A (https=)
CN (1) CN106659725A (https=)
AU (1) AU2015265620B2 (https=)
CA (1) CA2948438A1 (https=)
EA (1) EA033459B1 (https=)
IL (1) IL248838B (https=)
MX (1) MX365261B (https=)
PH (1) PH12016502271B1 (https=)
SG (2) SG10201906842WA (https=)
TW (1) TWI657818B (https=)
WO (1) WO2015181637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CA2606847A1 (en) 2005-05-09 2006-11-16 Warner-Lambert Company Llc Antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
CN102245605B (zh) * 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections

Also Published As

Publication number Publication date
IL248838B (en) 2020-05-31
TW201607537A (zh) 2016-03-01
TWI657818B (zh) 2019-05-01
US20180169104A1 (en) 2018-06-21
EA201692250A1 (ru) 2017-06-30
EP3148546A1 (en) 2017-04-05
PH12016502271A1 (en) 2017-02-06
JP6502387B2 (ja) 2019-04-17
JP2017516777A (ja) 2017-06-22
IL248838A0 (en) 2017-01-31
SG10201906842WA (en) 2019-08-27
US10238661B2 (en) 2019-03-26
EA033459B1 (ru) 2019-10-31
AU2015265620A1 (en) 2016-11-24
WO2015181637A1 (en) 2015-12-03
MX365261B (es) 2019-05-27
PH12016502271B1 (en) 2017-02-06
MX2016015632A (es) 2017-04-25
JP6502387B6 (ja) 2019-05-29
AU2015265620B2 (en) 2020-04-09
SG11201609404SA (en) 2016-12-29
CN106659725A (zh) 2017-05-10
CA2948438A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Spížek et al. Lincomycin, clindamycin and their applications
CN103565798B (zh) 广藿香酮及其衍生物的新用途
Kuriyama et al. Antimicrobial chemotherapy: significance to healthcare
JP6770584B2 (ja) 抗結核感染におけるカリマイシン（Ｋｅｌｉｍｙｃｉｎ）の応用
WO2018177218A1 (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
KR20170007818A (ko) 박테리아 감염의 치료를 위한 융합된，스피로환식 헤테로방향족 화합물
CN118416042A (zh) Lefamulin在鸟分枝杆菌复合群感染中的应用
Yamaguchi et al. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002
Langbang et al. A study on bacterial pathogens causing secondary infections in patients suffering from tuberculosis and their pattern of antibiotic sensitivity
Bassey et al. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates
CN117243966A (zh) 一种治疗耐碳青霉烯肺炎克雷伯氏菌感染的组合物
Shahrokhi et al. Bacterial biofilm in ventilator-associated pneumonia: a clinical concern
Quintiliani et al. Pharmacokinetic and pharmacodynamic considerations in antibiotic selection, with particular attention to oral cephalosporins
Abdu et al. Prevalence of qnr genes among multidrug resistance Staphylococcus aureus from clinical isolates
Khan et al. Antibiotic resistance pattern of methicillin resistant Staphylococcus aureus isolated from clinical specimens
CN100441580C (zh) 喹啉二酮衍生物及其在制备抗菌药物中的应用
JP2010519301A (ja) 感染を処置する方法
Momoh et al. Resistance pattern of urinary tract infection bacterial isolates to selected quinolones
Khan et al. Prevalence of multidrug resistant Staphylococcus aureus isolates in clinical specimens collected from local patients of Chittagong, Bangladesh
Zaki et al. Effect of some derivatives quinoline prepared on some pathogenic bacteria species compared with the 2-hydrazinobenzothiazole
Meskini et al. Antibiotic resistance in patients referred to Ali-ebn Abi-Taleb Hospital, Qom, Iran (2014-2015)
Bagde et al. Study of antibiotic susceptibility test of modern generation of drugs against upper respiratory tract pathogens
Bowman et al. Antimicrobial effects of isolated prodigiosin from Serratia marcescens in comparison to antibiotics
Zaki et al. Nosocomial Infection in Surgery Wards of Sohag University Hospital
JP2014530908A (ja) 細菌性感染症の治療のための医薬組成物及びキット

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161222

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200508

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211209

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220215

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211209

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I